Trial
NCT03956550
A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Regeneron Pharmaceuticals
Collaborators
—
Condition
Osteoarthritis of the Knee
Intervention
REGN5069
Why stopped
Regeneron has discontinued further clinical development of REGN5069, an antibody to GFRα3, which was previously being studied in osteoarthritis pain of the knee
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2021-07-01